CRDF PE Ratio & Valuation, Is CRDF Overvalued

Historical Valuation

Cardiff Oncology Inc (CRDF) is now in the Fair zone, suggesting that its current forward PS ratio of 518.46 is considered Fairly compared with the five-year average of -3.68. The fair price of Cardiff Oncology Inc (CRDF) is between 0.64 to 2.67 according to relative valuation method.

Relative Value

Fair Zone

0.64-2.67

Current Price：1.73

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cardiff Oncology Inc (CRDF) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cardiff Oncology Inc (CRDF) has a current Price-to-Book (P/B) ratio of 3.66. Compared to its 3-year average P/B ratio of 2.19, the current P/B ratio is approximately 67.00% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about 103.69% higher. Cardiff Oncology Inc (CRDF) has a Forward Free Cash Flow (FCF) yield of approximately -23.59%. Compared to its 3-year average FCF yield of -31.91%, the current FCF yield is approximately -26.07% lower. Relative to its 5-year average FCF yield of -29.29%, the current FCF yield is about -19.45% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRDF competitors is 89.09, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF.O) exhibits a P/S ratio of 518.46, which is 481.95% above the industry average. Given its robust revenue growth of 60.93%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRDF increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRDF in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRDF currently overvalued or undervalued?

What is Cardiff Oncology Inc (CRDF) fair value?

CRDF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cardiff Oncology Inc (CRDF) is between 0.64 to 2.67 according to relative valuation method.

How does CRDF's valuation metrics compare to the industry average?

The average P/S ratio for CRDF's competitors is 89.09, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF) exhibits a P/S ratio of 518.46, which is 481.95% above the industry average. Given its robust revenue growth of 60.93%, this premium appears sustainable.

What is the current P/B ratio for Cardiff Oncology Inc (CRDF) as of Mar 26 2026?

As of Mar 26 2026, Cardiff Oncology Inc (CRDF) has a P/B ratio of 3.66. This indicates that the market values CRDF at 3.66 times its book value.

What is the current FCF Yield for Cardiff Oncology Inc (CRDF) as of Mar 26 2026?

As of Mar 26 2026, Cardiff Oncology Inc (CRDF) has a FCF Yield of -23.59%. This means that for every dollar of Cardiff Oncology Inc's market capitalization, the company generates -23.59 cents in free cash flow.

What is the current Forward P/E ratio for Cardiff Oncology Inc (CRDF) as of Mar 26 2026?

As of Mar 26 2026, Cardiff Oncology Inc (CRDF) has a Forward P/E ratio of -3.59. This means the market is willing to pay $-3.59 for every dollar of Cardiff Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cardiff Oncology Inc (CRDF) as of Mar 26 2026?

As of Mar 26 2026, Cardiff Oncology Inc (CRDF) has a Forward P/S ratio of 518.46. This means the market is valuing CRDF at $518.46 for every dollar of expected revenue over the next 12 months.

CRDF Valuation